Aurobindo Pharma Ltd - AUROBINDO PHARMA Share Price

Sector: Pharmaceuticals | ISIN: INE406A01037
₹ 1,235.05 (0.42%) icon24 May, 2024, 12:00:00 AM

Aurobindo Pharma Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/24/2024 12:00:00 AM

    ₹ 1235.05 5.20 0.42
  • Open
  • ₹ 1,228.5
  • Prev. Close
  • ₹ 1,229.85
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 1,245.7
  • Day's Low
  • ₹ 1,221
  • 52 Week's High
  • ₹ 1,235.95
  • 52 Week's Low
  • ₹ 584.65
  • Book Value
  • ₹ 329.21
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 72,366.35
  • P/E
  • 36.61
  • EPS
  • 33.56
  • Divi. Yield
  • 0.61

Aurobindo Pharma Ltd Corporate Actions

27 Mar , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

10 Feb , 2024

12:00 AM

Dividend

Dividend amount: 1.5
Announcement date: 10 Feb , 2024

View Details

01 Feb , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

01 Feb , 2024

12:00 AM

09 Nov , 2023

12:00 AM

Dividend

Dividend amount: 3
Announcement date: 09 Nov , 2023

View Details

27 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

27 Oct , 2023

12:00 AM

28 Jul , 2023

12:00 AM

AGM

Announcement date: 28 Jul , 2023

View Details

03 Aug , 2023

12:00 AM

03 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

18 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

28 Jul , 2023

12:00 AM

BookCloser

View Details

No Record Found


Aurobindo Pharma Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Aurobindo Pharma Ltd SHAREHOLDING SNAPSHOT
24 May , 2024 | 06:39 PM

PROMOTER - TOTAL51.83%

Indian: 48.76%

Foreign: 3.072%

NON-PROMOTER - TOTAL 48.17%

Institutions: 41.29%

Non-Institutions: 6.87%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Aurobindo Pharma Ltd FINANCIALS

View Profit & Loss Graph

Aurobindo Pharma Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Aurobindo Pharma Ltd

  • K Ragunathan
  • Chairman & Independent Directo
  • Kambam Nityananda Reddy
  • Executive Director
  • M Sivakumaran
  • Executive Director
  • M Madan Mohan Reddy
  • Executive Director
  • P V Ramprasad Reddy
  • Non Executive Director
  • Savita Mahajan
  • Independent Non Exe. Director
  • Girish Paman Vanvari
  • Independent Non Exe. Director
  • P Sarath Chandra Reddy
  • Independent Non Exe. Director
  • Santanu Mukherjee
  • Independent Director
  • Deepali Pant Joshi
  • Additional Director

Summary

Aurobindo Pharma Limited (APL), one of the worlds top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The companys robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindos products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries. The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins... Read More


Reports by Aurobindo Pharma Ltd


Reports by Aurobindo Pharma Ltd

Company FAQ

No Record Found